Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Gjertsen

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Sykepleien|March 7, 1983
[Telemark Central Hospital at the head: Department budget with directors as responsible party]O K Gjertsen
European Journal of Cancer (Oxford, England : 1990)|January 25, 2000
Combination of GM-CSF with antitumour vaccine strategiesG Gaudernack, M K Gjertsen
Vox Sanguinis|August 15, 1998
Mutated Ras peptides as vaccines in immunotherapy of cancerM K Gjertsen, G Gaudernack
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 10, 1980
[Gore-Tex vascular prosthesis for peripheral vascular surgery]B L Lund, K Gjertsen, H Moen
British Journal of Cancer|December 1, 1996
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccinationM K Gjertsen, I Saeterdal, E Thorsby, et al.
Journal of Cataract and Refractive Surgery|January 29, 2003
Recurrence of secondary opacification and development of a dense posterior vitreous membrane in patients with myotonic dystrophyInger K Gjertsen, Kjell U Sandvig, Nils Eide, et al.
International Journal of Cancer|September 25, 1997
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutationM K Gjertsen, J Bjorheim, I Saeterdal, et al.
Cancer Immunology, Immunotherapy : CII|January 5, 2002
A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cellsI Saeterdal, M K Gjertsen, P Straten, et al.
International Journal of Cancer|March 12, 1998
Generation and characterization of gp100 peptide-specific NK-T cell clonesI Saeterdal, P thor Straten, J H Myklebust, et al.
Lancet (London, England)|November 25, 1995
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutationM K Gjertsen, A Bakka, J Breivik, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Sykepleien|March 7, 1983
[Telemark Central Hospital at the head: Department budget with directors as responsible party]O K Gjertsen
European Journal of Cancer (Oxford, England : 1990)|January 25, 2000
Combination of GM-CSF with antitumour vaccine strategiesG Gaudernack, M K Gjertsen
Vox Sanguinis|August 15, 1998
Mutated Ras peptides as vaccines in immunotherapy of cancerM K Gjertsen, G Gaudernack
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 10, 1980
[Gore-Tex vascular prosthesis for peripheral vascular surgery]B L Lund, K Gjertsen, H Moen
British Journal of Cancer|December 1, 1996
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccinationM K Gjertsen, I Saeterdal, E Thorsby, et al.
Journal of Cataract and Refractive Surgery|January 29, 2003
Recurrence of secondary opacification and development of a dense posterior vitreous membrane in patients with myotonic dystrophyInger K Gjertsen, Kjell U Sandvig, Nils Eide, et al.
International Journal of Cancer|September 25, 1997
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutationM K Gjertsen, J Bjorheim, I Saeterdal, et al.
Cancer Immunology, Immunotherapy : CII|January 5, 2002
A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cellsI Saeterdal, M K Gjertsen, P Straten, et al.
International Journal of Cancer|March 12, 1998
Generation and characterization of gp100 peptide-specific NK-T cell clonesI Saeterdal, P thor Straten, J H Myklebust, et al.
Lancet (London, England)|November 25, 1995
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutationM K Gjertsen, A Bakka, J Breivik, et al.
Pageof 2